Submissions for variant NM_000455.5(STK11):c.1175T>C (p.Met392Thr)

gnomAD frequency: 0.00001  dbSNP: rs876661013

Total submissions: 6

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000222367	SCV000279189	uncertain significance	not provided	2015-11-03	criteria provided, single submitter	clinical testing	This variant is denoted STK11 c.1175T>C at the cDNA level, p.Met392Thr (M392T) at the protein level, and results in the change of a Methionine to a Threonine (ATG>ACG). This variant has not, to our knowledge, been published in the literature as either a pathogenic or benign variant. STK11 Met392Thr was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Methionine and Threonine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. STK11 Met392Thr occurs at a position where amino acids with properties simliar to Methionine are tolerated across species and is located in a region required for binding of substrates and initiation of phosphotransfer (Hearle 2006). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available information, it is unclear whether STK11 Met392Thr is a pathogenic mutation or a benign variant. We consider it to be a variant of uncertain significance.
Invitae	RCV000697176	SCV000825773	uncertain significance	Peutz-Jeghers syndrome	2023-10-29	criteria provided, single submitter	clinical testing	This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 392 of the STK11 protein (p.Met392Thr). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with STK11-related conditions. ClinVar contains an entry for this variant (Variation ID: 234420). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt STK11 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color Diagnostics, LLC DBA Color Health	RCV000771390	SCV000903729	uncertain significance	Hereditary cancer-predisposing syndrome	2019-08-01	criteria provided, single submitter	clinical testing	This missense variant replaces methionine with threonine at codon 392 of the STK11 protein. Computational prediction tools and conservation analyses are inconclusive regarding the impact of this variant on the protein function. Computational splicing tools suggest that this variant may not impact RNA splicing. To our knowledge, functional assays have not been performed for this variant nor has this variant been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 2/238824 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Genome-Nilou Lab	RCV000697176	SCV002057955	uncertain significance	Peutz-Jeghers syndrome	2021-07-15	criteria provided, single submitter	clinical testing
Ambry Genetics	RCV000771390	SCV002633166	uncertain significance	Hereditary cancer-predisposing syndrome	2020-03-17	criteria provided, single submitter	clinical testing	The p.M392T variant (also known as c.1175T>C), located in coding exon 9 of the STK11 gene, results from a T to C substitution at nucleotide position 1175. The methionine at codon 392 is replaced by threonine, an amino acid with similar properties. In one study, this alteration was detected with a carrier frequency of 0.0001 in 12,490 male controls of Japanese ancestry. This variant was not detected in 7,051 unselected female breast cancer patients, 53 male breast cancer patients, and 11,241 female controls in the same study (Momozawa Y et al. Nat Commun, 2018 10;9:4083). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV003479069	SCV004222807	uncertain significance	not specified	2023-11-17	criteria provided, single submitter	clinical testing	Variant summary: STK11 c.1175T>C (p.Met392Thr) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8.4e-06 in 238824 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1175T>C in individuals affected with Peutz-Jeghers Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. The following publications have been ascertained in the context of this evaluation (PMID: 30287823, 36243179). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.